Keyword: Harvoni

Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.

The most expensive drugs in the U.S. feature commercial hits as well as lesser-known ones, with several Big Pharma products in the mix.

AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.

Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.

Merck lost out when a judge nixed $200 million in patent damages, citing misconduct and fabricated testimony. Now it wants the Supreme Court to intervene.

Gilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is on board.

Gilead's hepatitis C sales have eroded big-time, and the company is taking an unusual new tack that might deliver its drugs to new patients.

Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.

Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.